Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Open Access
- 29 October 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (10) , e007699
Abstract
Background: Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint inhibitor (ICI) efficacy in lung cancer and melanoma, but thorough characterization of this association in patients with gastric cancer is lacking. We aimed to determine the impact of H. pylori on survival in this population. Methods: This single-center, retrospective study included all ICI-treated individuals with metastatic gastric cancer and documented H. pylori status at Memorial Sloan Kettering between July 2013 and October 2021. H. pylori-positive status was defined as history of infection obtained via breath test, stool antigen test, histopathology, and/or chart documentation. Negative status was defined as explicitly negative testing, histopathology, and/or chart documentation. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Results: Of 215 included patients, 49 had documented history of H. pylori infection. Compared with H. pylori-negative patients, positive individuals tended to be younger, non-white, and Hispanic with non-cardia and intestinal-type gastric cancer. H. pylori-positive patients had significantly shorter median PFS (3.2 vs 6.8 months, HR 1.96, pH. pylori infection as an independent predictor of PFS (HR 3.04, pH. pylori infection was associated with inferior survival in ICI-treated patients with gastric cancer. This suggests H. pylori status may be a prognostic marker of immune responsiveness. Future studies are needed to elucidate immunoregulatory mechanisms and whether treatment of active infections would improve immunotherapy outcomes.Keywords
Funding Information
- National Cancer Institute of the National Institutes of Health (U01 CA265729)
- NIDDK of the National Institutes of Health (K08 DK125876)
- NIH/NCI Cancer Center (P30 CA008748)
This publication has 31 references indexed in Scilit:
- Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseasesMicrobiological Research, 2019
- The role of T helper 1-cell response in Helicobacter pylori-infectionMicrobial Pathogenesis, 2018
- Spotlight on protein N-terminal acetylationExperimental & Molecular Medicine, 2018
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Helicobacter pylori Therapy for the Prevention of Metachronous Gastric CancerNew England Journal of Medicine, 2018
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsScience, 2018
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience, 2018
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- Global burden of gastric cancer attributable toHelicobacterpyloriInternational Journal of Cancer, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009